REPL
Replimune Group, Inc.9.61
-0.34-3.42%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
753.84MP/E (TTM)
-Basic EPS (TTM)
-3.47Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
Replimune's Q3 FY2026 (ended December 31, 2025) showed R&D expenses climbing 10.7% y/y to $53.1M on IGNYTE-3 ramp-up and RP2 enrollment, while SG&A held steady at $18.7M amid BLA resubmission prep. Operating loss widened to $71.9M (y/y +8.9%, derived), matching net loss of $70.9M ($0.77/share) after minor other income offset interest on $47.6M debt (due 2027 at Prime+1.75%) and leases. Cash dipped to $269.1M from $483.8M y/y, burning $224.2M operationally (no FCF as capex minor); liquidity covers into Q1 2027 per MD&A. Subsequent $35M debt draw and $20.8M ATM bolster runway. FDA BLA resubmission accepted with PDUFA April 2026. Litigation risk lingers from RP1 CRL.
8-K
Loan amendment draws $35M
Replimune amended its loan agreement with Hercules Capital on January 29, 2026, drawing $35 million immediately while unlocking up to $155 million more across extended tranches tied to approval and revenue milestones into 2027. Amortization delays to October 2027, stretching cash runway to Q1 2027 amid $70.9 million Q3 net loss. RP1 BLA awaits FDA decision by April 10. Debt eases burn pressure.
8-K
RP1 ORR data, PDUFA April
Replimune released an updated corporate presentation on January 12, 2026, highlighting RP1's 24.8% ORR in 140 anti-PD-1 failed melanoma patients from IGNYTE, with deeper responses in visceral lesions versus prior therapy. PDUFA looms April 10, 2026; commercial team targets 150 accounts day one. RP2 advances in uveal melanoma and HCC. Cash stands at $269.2M.
10-Q
Q2 FY2026 results
Replimune's Q2 FY2026 results showed operating losses widening to $84.3M from $58.9M y/y, driven by ramped-up spending on the IGNYTE-3 confirmatory trial for RP1 and higher personnel costs, while net loss hit $83.1M versus $53.1M last year—largely due to $26.4M in SG&A for pre-launch prep. Cash burn accelerated with $158.2M used in operations for the half-year, leaving $323.6M in cash and equivalents at quarter-end, bolstered by $47.2M in long-term debt under the Hercules facility maturing 2027. The FDA accepted RP1's BLA resubmission in October, targeting a PDUFA date of April 2026, but regulatory hurdles persist. Free cash flow isn't disclosed in the 10-Q. Litigation risk looms from ongoing securities class actions tied to the prior CRL.
8-K
FDA accepts RP1 BLA resubmission
Replimune's BLA resubmission for RP1 in advanced melanoma gained FDA acceptance on October 20, 2025, targeting approval by April 10, 2026, after addressing a July complete response letter. The company reported a Q2 net loss of $83.1 million, up from $53.1 million last year, driven by higher R&D costs for IGNYTE-3 and RP2 trials, while cash reserves stand at $323.6 million to fund operations into late 2026. RP1 showed strong 44% ORR in acral melanoma. Cash burn accelerates commercialization prep.
AIM
AIM ImmunoTech Inc.
1.38+0.06
ALT
Altimmune, Inc.
5.03-0.25
BVAXD
BioVaxys Technology Corp.
0.15-0.03
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
CUE
Cue Biopharma, Inc.
0.41-0.05
IMNN
Imunon, Inc.
3.88-0.09
IMRX
Immuneering Corporation
5.74-0.04
ONCY
Oncolytics Biotech Inc.
1.04+0.12
RENB
Lunai Bioworks Inc.
1.42+0.00
RPTX
Repare Therapeutics Inc.
2.23+0.03